Physician profile
Jon Ryan Ward
NPI 1720039829
$14,628.05
in general payments reported to CMS, 2019-2025
30 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 80% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,156 · 2020: $863 · 2021: $1,602 · 2022: $1,407 · 2023: $5,390 · 2024: $2,894 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,878 · Food and Beverage: $4,627 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,877.99 |
| Food and Beverage | $4,626.58 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,265.79 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Organogenesis INC. | $2,736.81 | 2021-2025 | Puraply, Apligraf, Simplimax |
| Sun Pharmaceutical Industries INC. | $1,162.56 | 2019-2025 | Blu-U, Ilumya |
| Lilly USA, LLC | $684.52 | 2019-2025 | Taltz, Ebglyss |
| Allergan, INC. | $664.02 | 2021-2022 | |
| Genzyme Corporation | $636.82 | 2019-2025 | |
| Amgen INC. | $370.41 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $305.39 | 2020-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $278.49 | 2019-2023 | |
| Ucb, INC. | $257.81 | 2019-2024 | Bimzelx |
| Janssen Biotech, INC. | $211.52 | 2019-2024 | Tremfya |
| Genentech USA, INC. | $135.37 | 2019-2024 | Erivedge |
| Sanofi-Aventis U.S. LLC | $130.67 | 2019-2020 | |
| Pfizer INC. | $119.60 | 2019-2022 | |
| Convatec INC. | $115.18 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $60.99 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $58.27 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $54.23 | 2019-2023 | Adbry |
| Incyte Corporation | $49.86 | 2022 | |
| Fresenius Kabi USA, LLC | $46.36 | 2023 | Idacio |
| Angiodynamics, INC. | $44.01 | 2020 | |
| Strata Skin Sciences, INC. | $37.27 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $36.88 | 2019 | |
| Triad Life Sciences INC. | $31.12 | 2022 | |
| Kerecis Limited | $30.56 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Galderma Laboratories, L.P. | $28.98 | 2019-2025 | Nemluvio |
| Dermira, INC. | $25.74 | 2019-2020 | |
| Boston Scientific Corporation | $23.76 | 2024 | Watchman Flx |
| Celgene Corporation | $12.57 | 2019 | |
| Mayne Pharma Commercial LLC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.